We thank Drs. McLean and Schwarz
1
for their interest in our work. We agree that claims-based data base research comes
with several limitations,
2
,3
which we address in our manuscript. Notably, there could be error in the reporting
of claims, the possibility of coding bias, and inadequate definitions of comorbidities
and complications. Furthermore, because of the reliance on diagnosis and procedural
codes, granular rationale for clinical decision-making that is not codified (ie, removal
of a spinal cord stimulator device due to poor surgical technique) cannot be reliably
detected with claims-based data base research. Thus, claims-based research is intended
to be hypothesis generating, and we encourage physicians to explore the observations
from our work in prospective studies.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe toAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Response to: “Identifying Predictors for Early Percutaneous Spinal Cord Stimulator Explant at One and Two Years: A Retrospective Database Analysis”.Neuromodulation. 2023; 26: 709
- Understanding the statistics and limitations of large database analyses.Spine (Phila Pa 1976). 2014; 39: 1311-1312
- Overview and limitations of database research in anesthesiology: a narrative review.Anesth Analg. 2021; 132: 1012-1022
- Odds ratios-current best practice and use.JAMA. 2018; 320: 84-85
Article info
Publication history
Accepted:
January 25,
2023
Received:
January 25,
2023
Footnotes
Conflict of Interest: Tristan Weaver provides consulting services to Medtronic and received research support from Medtronic, Boston Scientific, SPR Therapeutics, and Heron Pharmaceuticals. Nasir Hussain reported no conflict of interest.
Identification
Copyright
© 2023 Published by Elsevier Inc. on behalf of the International Neuromodulation Society.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Response to: “Identifying Predictors for Early Percutaneous Spinal Cord Stimulator Explant at One and Two Years: A Retrospective Database Analysis”NeuromodulationVol. 26Issue 3
- PreviewWe write to express our views on the recent study published in your journal, titled “Identifying Predictors for Early Percutaneous Spinal Cord Stimulator Explant at One and Two Years: A Retrospective Database Analysis.”1 Although the study is notable for its large sample size and the valuable insights it provides into the incidence and predictors of spinal cord stimulator (SCS) explant, we believe there are several limitations that should be acknowledged and addressed.
- Full-Text
- Preview
